OREX - Orexigen Therapeutics, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD

Orexigen Therapeutics, Inc.

3344 North Torrey Pines Court
Suite 200
La Jolla, CA 92037
United States

IndustryDrug Manufacturers - Other
Full Time Employees132

Key Executives

Mr. Michael A. Narachi M.S., M.B.A.Pres, Chief Exec. Officer & Director1.15MN/A58
Dr. Thomas R. Cannell D.V.M.Exec. VP, COO & Pres of Global Commercial Products691.11kN/A55
Mr. Thomas P. LynchExec. VP, Gen. Counsel & Sec.552.37kN/A50
Mr. Jason KeyesSr. VP & CFON/AN/A46
Stephen A. MogliaChief Accounting Officer, VP and ControllerN/AN/AN/A
Amounts are as of December 31, 2016 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Orexigen Therapeutics, Inc., a biopharmaceutical company, focuses on the development of pharmaceutical products primarily in the United States, Europe, and South Korea. It offers Contrave for the treatment of obesity. The company also offers Contrave under the Mysimba brand name. Orexigen Therapeutics, Inc. was founded in 2002 and is headquartered in La Jolla, California.

Corporate Governance

Orexigen Therapeutics, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.